NYSE:ABBVBiotechs
Is EMA Backing For MAVIRET And Boey Reshaping The Investment Case For AbbVie (ABBV)?
AbbVie recently received positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting approval of MAVIRET for acute hepatitis C and Boey for glabellar lines across the European Economic Area, backed by Phase 3 data showing high cure rates and favorable safety profiles.
These dual regulatory wins in virology and aesthetics highlight how AbbVie is widening its treatment footprint in Europe across both high-need and elective care...